Takeda Abbott Pharmaceuticals Sues Atrix

Law360, New York (November 14, 2003, 12:00 AM EST) -- Takeda Abbott Pharmaceuticals Products, Takeda Chemical Industries and Wako Pure Chemical Industries sued Atrix Laboratories and its licensee, Sanofi-Synthelabo, alleging that Atrix's Eligard delivery system infringes on a patent for a biodegradable high molecular polymer excipient held by Takeda Chemical Industries.

The Eligard products use Atrix's proprietary Atrigel sustained-release drug delivery technology, Atrix said. The liquid Eligard products are injected subcutaneously with a small gauge needle forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed.

Atrix chief executive David...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.